Swiss National Bank’s Rubius Therapeutics, Inc RUBY Stock Holding History

Swiss National Bank’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-95,600	Closed	-$527K	–	2819
2022 Q1	$527K	Buy	95,600 +6,700	+8%	+$42.6K	﹤0.01%	2595
2021 Q4	$861K	Hold	88,900	–	–	﹤0.01%	2530
2021 Q3	$1.59M	Buy	88,900 +8,400	+10%	+$183K	﹤0.01%	2196
2021 Q2	$1.97M	Sell	80,500 -2,400	-3%	-$60K	﹤0.01%	2109
2021 Q1	$2.2M	Buy	82,900 +10,000	+14%	+$146K	﹤0.01%	1941
2020 Q4	$553K	Hold	72,900	–	–	﹤0.01%	2446
2020 Q3	$365K	Hold	72,900	–	–	﹤0.01%	2405
2020 Q2	$436K	Buy	72,900 +12,000	+20%	+$70.8K	﹤0.01%	2403
2020 Q1	$271K	Hold	60,900	–	–	﹤0.01%	2365
2019 Q4	$579K	Buy	60,900 +1,500	+3%	+$14.5K	﹤0.01%	2382
2019 Q3	$466K	Hold	59,400	–	–	﹤0.01%	2381
2019 Q2	$934K	Buy	+59,400	New	+$958K	﹤0.01%	2152

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Swiss National Bank's RUBY Position: Q2 2022 in Review

Swiss National Bank sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 95,600 shares — an estimated $527K sold.

Swiss National Bank first reported a position in RUBY in Q2 2019 and held it in 12 quarters. The position peaked at $2.2M in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Swiss National Bank reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Swiss National Bank sold 95,600 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $527K.
Swiss National Bank first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 12 quarters.
Swiss National Bank's Rubius Therapeutics, Inc position peaked at $2.2M in Q1 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.